Odyssey Therapeutics
Company
Key facts about this entity
- Founded 2021; headquartered in Boston; listed on Nasdaq (ODTX) since 8 May 2026
- IPO: $18 a share, about $304 million raised, valued at about $900 million (May 2026)
- Private rounds: Series A $218 million (2021) to Series D $213 million (September 2025), valuations undisclosed
- Lead programme: OD-001 (RIPK2 inhibitor) in ulcerative colitis
- TUM link: scientific co-founder Florian Schmidt (TUM biochemistry, 2003-2007)
- No private or public valuation of $1 billion or more found (as of October 2026)
Entity Profile
Overview
Odyssey Therapeutics, Inc. is a clinical-stage biotechnology company developing small-molecule and biologic drugs for autoimmune and inflammatory diseases. Its lead programme, OD-001, is a RIPK2 inhibitor in ulcerative colitis.
Why this entity matters
Odyssey is on the Technical University of Munich's August 2026 list of unicorns founded by TUM alumni, supplied to Startuprad.io by UnternehmerTUM's press office in October 2026. Its TUM link is scientific co-founder Florian Schmidt (TUM biochemistry, 2003-2007), now at the University of Bonn. Startuprad.io found no private valuation of $1 billion or more, and its market value at and after its May 2026 IPO stayed below $1 billion. No UnternehmerTUM programme or UVC Partners investment has been documented.
Company history and product
Founded in 2021 by Gary Glick with scientific co-founders from Bonn, Odyssey raised a $218 million Series A (2021), a $168 million Series B (2022), a $101 million Series C (2023) and a $213 million Series D (September 2025), with valuations undisclosed. It listed on Nasdaq on 8 May 2026 at $18 a share, raising about $304 million and valued at about $900 million. In October 2026 it reported Phase 2a results for OD-001 in ulcerative colitis.
Role in the European start-up landscape
Odyssey is a US company. Its connection to Germany runs through its Bonn-based scientific co-founders, one of whom studied at TUM.
Selected relationships and affiliations
Founders: Gary D. Glick (founder, CEO), Florian Schmidt, Eicke Latz and Felix Meissner (scientific co-founders). Investors include OrbiMed, SR One, TPG Life Sciences Innovations, Lightspeed and Foresite Capital.
Startuprad.io relevance
Odyssey Therapeutics is covered in Startuprad.io's Unicorn Atlas special on the 23-company list of unicorns founded by TUM alumni, which UnternehmerTUM's press office supplied to Startuprad.io in October 2026. The special checks each company's TUM link, its billion-dollar milestone and any documented UnternehmerTUM programme or investment.
Public source context
This profile is drawn from public sources including Odyssey Therapeutics, Fierce Biotech, Reuters, University of Bonn and Startuprad.io coverage. Time-sensitive figures, including valuations and ownership, are reported with their dates and should be re-verified against primary sources before commercial use.
Startuprad.io coverage of Odyssey Therapeutics
Odyssey Therapeutics appears in the following Startuprad.io interviews, news and analysis.
Exclusive: The 23-Unicorn List UnternehmerTUM Gave Us — and Where Its Role Is on Record
Published: 26 October 2026
Last updated: 26 October 2026
Coverage type: Analysis
https://www.startuprad.io/post/exclusive-the-23-unicorn-list-unternehmertum-gave-us-and-where-its-role-is-on-record
About this record. This is the public Level 1 layer of Startuprad.io's entity intelligence architecture. Startuprad.io's deeper entity intelligence may include extended profiles, verified relationships, source trails, historical development, monitoring, news signals, custom entity sets, and analytical relationship mapping. These deeper layers are available through Startuprad.io's research, intelligence, and enterprise services.
Need deeper entity intelligence? Startuprad.io provides extended profiles, monitored entity sets, relationship analysis, source-backed research, and custom intelligence services for companies, investors, and institutions. → https://www.startuprad.io/become-a-partner
For biotech founders and investors, our members-only briefings follow how European academic co-founders turn research into US-listed companies.
▶ YouTube Membership: https://www.youtube.com/startupradio/join
✉️ Substack: https://startupradio.substack.com/subscribe
About Startuprad.io
Startuprad.io is a European B2B media, data and intelligence platform. It provides structured entity and ecosystem data, source-backed research, datasets and AI/training-data solutions, as well as strategic visibility and access to a professional European audience of founders, investors, executives and B2B decision-makers.
Organizations use Startuprad.io for intelligence and research, structured data and AI applications, executive and company positioning, and trusted B2B reach across Europe.
Canonical record: https://www.startuprad.io/entities/odyssey-therapeutics